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Objectives/Hypothesis: The objective of this
study was to determine the predictors of sleep quality
among head and neck cancer patients 1 year after
diagnosis.
Study Design: This was a prospective, multisite
cohort study of head and neck cancer patients (N ¼
457).
Methods: Patients were surveyed at baseline
and 1 year after diagnosis. Chart audits were also
conducted. The dependent variable was a self-
assessed sleep score 1 year after diagnosis. The inde-
pendent variables were a 1 year pain score, xerosto-
mia, treatment received (radiation, chemotherapy,
and/or surgery), presence of a feeding tube and/or tra-
cheotomy, tumor site and stage, comorbidities, depres-
sion, smoking, problem drinking, age, and sex.
Results: Both baseline (67.1) and 1-year post-
diagnosis (69.3) sleep scores were slightly lower than
population means (72). Multivariate analyses showed
that pain, xerostomia, depression, presence of a tra-
cheotomy tube, comorbidities, and younger age were
statistically significant predictors of poor sleep 1 year
after diagnosis of head and neck cancer (P < .05).
Smoking, problem drinking, and female sex were
marginally significant (P < .09). Type of treatment
(surgery, radiation and/or chemotherapy), primary tu-
mor site, and cancer stage were not significantly asso-
ciated with 1-year sleep scores.
Conclusions: Many factors adversely affecting
sleep in head and neck cancer patients are potentially
modifiable and appear to contribute to decreased
quality of life. Strategies to reduce pain, xerostomia,
depression, smoking, and problem drinking may be
warranted, not only for their own inherent value, but
also for improvement of sleep and the enhancement
of quality of life.
Key Words: Head and neck cancer, sleep, pain,
xerostomia.
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INTRODUCTION
Sleep disturbances are a common complaint in can-
cer patients with a reported incidence ranging from 30%
to 75%.1 Sleep disturbances have been shown to
decrease quality of life, decrease work productivity,
increase utilization of health care resources, decrease
mental health, and serve as a predictor of other compli-
cations in cancer patients.2–4 A recently published study
by our team demonstrated that sleep disorders are com-
mon among head and neck cancer patients.5 However,
the causes of sleep disturbances among head and neck
cancer patients are unclear and have not been well stud-
ied. Head and neck cancer patients have a high
prevalence of pain (70%) compared to other cancer sites
(52%–60%), and pain is associated with insomnia.6 Pain
is often correlated with depression among cancer
patients, and the majority of depressed patients report
insomnia.7,8 Depression is also correlated with nicotine
and alcohol use, which are both common among head
and neck cancer patients and have an adverse effect on
sleep quality.9,10 Radiation therapy to treat head and
neck tumors can also contribute to obstructive sleep
apnea and xerostomia (dry mouth), the latter of which
requires excessive drinking and urination during the
night.11,12
Although there is reason to believe that head and
neck cancer patients are at even greater risk for sleep
disorders than other cancer patients secondary to high
rates of pain, depression, nicotine and alcohol use, ob-
structive sleep apnea, surgical alterations or radiation
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therapy, and xerostomia, the etiology and nature of
these sleep disorders are largely anecdotal and
unknown. Although efficacious interventions are avail-
able to treat sleep disorders, it is first necessary to
determine the source of the sleep disorders prevalent in
this population. Therefore, we hypothesized that specific
clinical variables would affect sleep quality in head and
neck patients in ways that might influence oncologic
treatments themselves as well as the approach to medi-
cal management after the completion of therapy. Thus,
the objective of this study was to determine the predic-




The data were collected from a prospective cohort study of
patients enrolled in the University of Michigan Head and Neck
Cancer Specialized Programs of Research Excellence study ti-
tled Molecular Markers, Health Behaviors, and Comorbidities
as Predictors of Tumor Recurrence, Survival, and Quality of
Life in Head and Neck Cancer. This substudy was designed to
determine the predictors of poor sleep among head and neck
cancer patients 1 year after diagnosis. The dependent variable
was a self-assessed sleep score 1 year after diagnosis. The inde-
pendent variables were pain, xerostomia, treatment received
(radiation, chemotherapy, and/or surgery), presence of a feeding
tube and/or tracheotomy, tumor site and stage, comorbidities,
depression, smoking, problem drinking, age, and sex.
SUBJECTS
Subjects were recruited from the University of
Michigan Health System, the Henry Ford Health Sys-
tem, and the Veterans Affairs Ann Arbor Healthcare
System otolaryngology clinics (Ann Arbor and Detroit,
MI). Newly diagnosed patients with head and neck squa-
mous cell carcinoma were eligible to participate.
Excluded were those: 1) <18 years of age; 2) pregnant;
3) non-English speaking; 4) psychologically or mentally
unstable (such as patients with suicidal ideation, acute
psychosis, or dementia); or 5) with non-upper aerodiges-
tive tract cancer (such as thyroid or cutaneous
neoplasms). Of 1,054 patients initially approached for
the larger study, 823 agreed to participate. Of those, 66
subjects were excluded leaving a sample of 757 in the
larger study. For this substudy, an additional 84 did not
complete the baseline health survey and 165 did not
return a 1-year health survey. Additionally, another 51
subjects were excluded from these analyses due to miss-
ing data, resulting in a sample of 457. Retention of the
sample was determined primarily by mortality. Of the
165 patients not retained, 110 (67%) had died.
PROCEDURES
Institutional review board approval was obtained at
each site before the study. For the larger study, which
began recruitment in 2003, research assistants
approached patients in the waiting rooms of otolaryngol-
ogy clinics for participation in the study. The research
assistants obtained informed consent from all eligible
patients who agreed to participate, who then were asked
to complete a written survey on quality of life, health
behaviors, and demographics. Clinical measures were
collected by chart abstraction. Subjects were then resur-
veyed 1 year after diagnosis.
Measures
Dependent variable. Although sleep quality can
be assessed objectively by a number of different modal-
ities, including polysomnography, sleep latency testing,
and actigraphy, self-reported questionnaires serve as a
noninvasive substitute that have been validated and
verified as useful instruments for research and clinical
practice. The Medical Outcomes Study (MOS) sleep mea-
sure represents four constructs related to sleep health:
sleep disturbance, adequacy of sleep, somnolence, and
respiratory problems.13 It has been validated in two pilot
studies, in a large sample of chronically ill patients, and
in patients enrolled in ongoing clinical trials.2,14 The
MOS sleep measure was administered initially and then
again 1 year after diagnosis. The short-form index of six
questions was used, which were averaged and trans-
formed to a scale of 0 to 100, with 0 being the worst and
100 the best (mean score in a normal population was
72).15
Independent variables. Pain was measured using
the bodily pain score from the validated Short Form-36
(SF-36); low scores indicate worse pain.16 Xerostomia
was measured by a question taken from the validated
Head and Neck Quality of Life, a disease-specific qual-
ity-of-life instrument for patients with head and neck
cancer that asked: As a result of your head and neck
condition or treatment, over the past 4 weeks, how
much have you been bothered by problems with dryness
in your mouth while eating? The question was rated on
a 5-point Likert scale as either not at all, slightly, mod-
erately, a lot, or extremely.17
Comorbidities were measured by chart abstraction
using the Adult Comorbidity Evaluation-27 (ACE-27), a
validated comorbidity index designed to evaluate levels
of comorbidity for predicting survival and quality of life
in head and neck cancer patients.18 The score on the
ACE-27 was classified into two groups: moderate/severe
comorbidity versus none/mild comorbidity. Other clinical
measures abstracted from the patient medical records
included tumor site, tumor stage, and treatment modal-
ity (including radiation, chemotherapy, and any head
and neck surgery). Information on whether the patient
had a feeding tube or tracheotomy at the time of the
1-year survey was also recorded. Tumor site was segre-
gated into three groups for multivariate analysis: oral
cavity/sinus; pharynx (oropharynx, hypopharynx, naso-
pharynx, or unknown primary); and larynx. Tumor stage
was dichotomized into stage IV versus all others.
Depression was measured using the Geriatric
Depression Scale-Short Form (GDS-SF); a score of 4 or
higher on the GDS-SF indicates probable depression.19
Anyone smoking cigarettes within the last month was
considered a smoker. The 10-item Alcohol Use Disorder
Identification Test (AUDIT) was used to assess the level
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of alcohol intake and related problems; a score of 8 or
higher on the AUDIT indicates high risk of alcohol-
related disorders.20 Because age and sex have been asso-
ciated with sleep disturbances, they were also included
in the analyses as predictor variables.21,22
Data Analysis
Descriptive statistics were calculated for all meas-
ures; frequencies and percentages were presented for
categorical variables, and means and standard devia-
tions were presented for quantitative measures.
Bivariate associations between the predictor variables
and the outcome of 1-year sleep scores were calculated
using Student t tests and analysis of variance. Student t
tests were used to compare the sleep scores among
patients with glottic cancer who were treated with
organ-sparing therapy with the scores of patients
treated with laryngectomy. Multiple linear regression
was used to determine significant predictors of 1-year
MOS sleep score.
RESULTS
Quality of Sleep Characteristics
The quality of sleep characteristics are shown in
Table I. The mean sleep score at the time of diagnosis
was 67.1. One year after diagnosis, the mean sleep score
was slightly improved at 69.3 (P ¼ .01). At 1 year, the
mean SF-36 bodily pain score was 65.3. Forty-three per-
cent of patients described their xerostomia as ‘‘a lot’’ or
‘‘extremely’’ bothersome at 1 year. Most had radiation,
and over one half had chemotherapy and radiation. Most
had cancer of the pharynx, over one half were stage IV,
and over two thirds had none or mild comorbidities.
About 36% had primary site surgery, 42% had a neck
dissection, only 17% had a feeding tube, and <4% had a
tracheotomy. One year after diagnosis, 19% of patients
continued to smoke, 11% were problem drinkers, and
49% had positive depression screens. The mean age was
58 and over three quarters were male.
Bivariate Analysis
Bivariate analysis (Table II) showed that 1 year af-
ter diagnosis, increasing age in decades was statistically
associated with higher sleep scores (P < .001). Female
patients had significantly worse sleep at 1 year than
male patients (P ¼ .04).
At 1 year, the bodily pain domain of the SF-36 was
highly associated with the sleep score, with sleep scores
4.35 points higher for every 10 points improved bodily
pain score (P < .001). The 1-year bodily pain score alone
explained 30% of the variance in the 1-year sleep score.
Xerostomia was highly correlated with 1-year sleep
scores, with an average 25-point decrement in sleep
scores between patients who had no complaints of dry-
ness while eating versus those who were extremely
bothered by dryness while eating (P < .001).
At 1 year after diagnosis, neither radiation, chemo-
therapy, nor any type of surgery (tumor extirpation from
primary site or neck, laryngectomy, or reconstruction)
affected sleep scores. Patients with glottic cancer who
were treated with larynx-preserving therapy (n ¼ 97)
had no differences in sleep scores compared with
patients treated with laryngectomy (n ¼ 19) (P ¼ .99).
Patients who had a feeding tube at 1 year had a lower
sleep score when compared to patients who did not (P ¼
.005). Patients who had a tracheotomy at 1 year also
had significantly lower sleep scores compared to those
who did not (P ¼ .001). Cancer site and stage were not
associated with mean sleep score. At 1 year, moderate or
severe comorbidities were only marginally associated
with worse sleep scores (P ¼ .068).
Depression and current smoking were both associ-
ated with large decrements in sleep score (P < .001).
Patients with alcohol problems at 1 year had signifi-
cantly worse sleep than those without an alcohol
problem (P < .001).
Multivariate Analysis
Multivariate analyses (Table III) showed that SF-36
bodily pain score, xerostomia, presence of a tracheotomy,
moderate/severe comorbidities, depressive symptoms at
1 year, and younger age were statistically significant
predictors of worse sleep scores. A 1-point decrement in
bodily pain score correlated with a nearly 2.2-point dec-
rement in sleep score. A one-level decrement in the
patient’s score for xerostomia was associated with a 2.8-
point decrease in sleep score.
Those with a current tracheotomy at 1 year aver-
aged an 8.2-point decrement in sleep score. Although
comorbidities were only marginally significant in the
bivariate analyses, it became significant in the multivar-
iate analyses; patients with moderate/severe
comorbidities had a 4.0-point lower score when com-
pared to patients with none/mild comorbidities.
Depression was associated with a 14.3-point decrease in
sleep score. Older patients had improved sleep scores
(2.4 points for every decade in age).
Although presence of a feeding tube was significant
on the bivariate analysis, it was no longer significant on
the multivariate analysis. Moreover, smoking, alcohol
problem, and sex were significant on the bivariate analy-
ses, but were only marginally significant in the
multivariate analyses. Radiation, chemotherapy, surgery,
cancer site, and cancer stage were not significant in ei-
ther the bivariate or multivariate analyses.
DISCUSSION
Sleep scores did not change dramatically from the
time of diagnosis to 1 year after treatment. However, the
scores at both time points are worse than the mean
score for a normal population. It is likely that patients
at baseline had poor sleep directly related to symptoms
of their neoplasm, such as pain, coupled with anxiety
related to their recent cancer diagnosis. Although one
might expect that some or all of these factors would pre-
sumably improve after treatment, pain, xerostomia, and
other discomforts related to treatment as well as fear of
recurrence are likely to persist after treatment. This
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may explain the relatively minor change in sleep scores
from baseline to 1 year. Many variables contribute to the
quality of sleep of head and neck cancer patients as out-
lined below.
Pain
Bodily pain was a strong predictor of worsened sleep
scores. The relationship between pain and sleep in head and
neck cancer patients has been previously demonstrated.23
Patients with chronic pain have identified sleep-related com-
plaints as one of the most important aspects of their daily
life on which pain has a deleterious effect.24 Pain is common
among head and neck cancer patients, is commonly associ-
ated with insomnia, and clearly impacts health-related
quality of life.25 This substantiates the need to aggressively
treat pain in the head and neck cancer population.
Xerostomia
Xerostomia has been demonstrated to adversely
affect quality of life in patients undergoing external
beam radiation therapy, specifically with regard to fa-
tigue and insomnia.11 Xerostomia most likely negatively
impacts the sleep cycle because affected patients experi-
ence discomfort, and drink large quantities of liquids
during the night, thereby fostering nocturnal micturi-
tion, frequent awakenings, and difficulty returning to
sleep once awake. Hence, any potential alterations in
treatment that might preserve salivary function could
conceivably improve sleep quality.
Intensity-modulated radiation therapy (IMRT)
delivers increased doses of radiation to tumor or high-
risk tissues, with relative sparing of functional tissue
such as the salivary glands.26 The technique of sparing
parotid glands in head and neck cancer external beam
radiation protocols has been proven feasible and effec-
tive in preventing xerostomia.27 Xerostomia that
disrupts sleep may also be related to submandibular
gland dysfunction, as these glands produce the majority
of basal salivary flow.28 The submandibular glands are
not spared with IMRT; their role in xerostomia-related
sleep disturbances has not been examined critically.
TABLE I.
Characteristics of Head and Neck Cancer Population (N 5 457).
Variable No. Mean SD Range
Age 457 58.3 10.6 23-92
Baseline sleep score 438 67.1 20.8 0-100
1-yr sleep score 457 69.3 20.6 0-100
Bodily pain, SF-36, 1 yr 457 65.3 26.0 0-100
Variable No. %
Xerostomia, 1 yr
Not at all 96 21.0
Slightly 78 17.1
Moderately 85 18.6













































Smoked past month, 1 yr
Yes 86 18.8
No 371 81.2






SD ¼ standard deviation; SF-36 ¼ Short Form-36; ACE-27 ¼ Adult
Comorbidity Evaluation-27.
*Pharynx cancer site includes Oropharynx, Hypopharynx, Nasophar-
ynx, and Unknown Primary.
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Future studies from our institution are planned to test
whether salivary gland-sparing IMRT explains the bet-
ter functional outcomes in patients subjected to
radiation who do not complain of dry mouth. Based on
our results, minimizing xerostomia appears worthwhile
to improve postradiation sleep quality.
Treatments and Cancer Site and Stage
Although reports of the effect of radiation treatment
and sleep have been mixed, we did not find an association
between radiation and sleep quality.23,29 Nor did we find
an association between chemotherapy, surgery, and pres-
ence of a feeding tube with sleep scores. Laryngectomized
patients did not have any difference in sleep scores com-
pared with those patients with glottic cancer who
preserved their larynx; this directly contrasts with the
findings of Boscolo-Rizzo et al.30 Moreover, cancer site and
cancer stage did not predict sleep quality. Perhaps the
numerous control variables in this study were able to
tease out the fact that symptoms, such as pain and xero-
stomia, were more predictive of sleep quality than the
actual treatments themselves. It may appear incongruous
that patients receiving external beam radiation did not
have lower sleep scores despite the strong association
between xerostomia and worse sleep. We postulate that
the size of our cohort, with its large percentage of patients
who received some type of external beam radiation (either
salivary-sparing or not) allowed for the statistical analysis
to distinguish between those patients with xerostomia
(approximately one half of those who received radiation)
and those who did not complain of dry mouth despite also
having received radiation. We expect that salivary gland-
sparing techniques help prevent or limit the severity of
xerostomia. As a result, xerostomia would be expected to
be a stronger predictor of worse sleep scores than would
external beam radiation itself. We therefore hypothesize
that patients receiving parotid-sparing radiation therapy
would have better sleep scores than patients receiving
non-parotid sparing radiation therapy.
On the other hand, the presence of a tracheotomy
tube 1 year after diagnosis was associated with a
decrease in sleep score, and remained an independent
predictor of 1-year sleep in the multivariate regression.
Multiple studies suggest that head and neck cancer
patients are predisposed to obstructive sleep apnea,
although the data are far from conclusive.31 Theoreti-
cally, the presence of a tracheotomy would improve sleep
in this patient group, which would not correlate with our
TABLE II.
Bivariate Associations With 1-Year Sleep Score.
Variable Parameter Estimate Standard Error P Value
Age (decades) 3.8 0.9 <.001
SF-36 pain (10 points), 1 yr 4.35 0.3 <.001
No. Mean Sleep Score SD P Value
Xerostomia, 1 yr <.001
Not at all 96 78.6 17.1
Slightly 78 70.7 18.2
Moderately 85 71.8 18.6
A lot 122 69.0 20.1
Extremely 76 53.5 21.4
Radiation .378
Yes 389 68.9 20.9
No 68 71.3 19.1
Chemotherapy .194
Yes 284 68.3 21.0
No 173 70.9 19.9
Surgery (any) .974
Yes 240 69.3 20.6
No 217 69.2 20.7
Primary site surgery .732
Yes 162 68.8 20.2
No 295 69.5 20.8
Neck dissection .796
Yes 191 69.6 20.9
No 266 69.1 20.4
Feeding tube, 1 yr .005
Yes 77 63.2 20.3
No 380 70.5 20.5
Tracheotomy,1 yr .001
Yes 17 53.3 25.8
No 440 69.9 20.2
Cancer site .348
Pharynx* 247 70.3 20.7
Oral cavity/sinus 94 66.7 20.2
Larynx 116 69.1 20.7
Stage 4 .452
Yes 266 68.7 21.8
No 191 70.1 18.8
Comorbidity .068
None/mild 321 70.4 20.3
Moderate/severe 136 66.6 21.0
Depressed, 1 yr <.001
Yes 176 54.7 18.2
No 281 78.4 16.3
Smoked past month, 1 yr <.001
Yes 86 57.6 20.7
No 371 72.0 19.6
Alcohol problem, 1 yr <.001
Yes 49 54.4 20.6




No. Mean Sleep Score SD P Value
Sex .040
Male 353 70.3 20.8
Female 104 65.6 19.6
Short Form-36 ¼ SF-36; SD ¼ standard deviation.
†The SF-36 Bodily Pain Score and the MOS Sleep Score are meas-
ured on a scale of 0–100 with 100 being the best score.
*Pharynx cancer site includes Oropharynx, Hypopharynx, Nasophar-
ynx, and Unknown Primary.
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findings assuming there was a significant prevalence of
obstructive sleep apnea (which was not specifically eval-
uated). Although an upper airway obstruction may be
bypassed, issues such as secretion management and suc-
tioning requirements may adversely affect sleep.
Moreover, the presence of a tracheotomy may simply
reflect globally poor function or decreased patency of the
upper aerodigestive tract due to persistent post-treatment
edema or other local tissue effects.
Comorbidities
Moderate/severe comorbidities were associated with
worse sleep scores in both bivariate and multivariate
analysis. Comorbid conditions (specifically those associ-
ated with psychological well-being) can easily be
considered risk factors for worsened sleep.32 The associa-
tion between increased mortality and comorbidity in head
and neck cancer has been proven, although data estab-
lishing the relationship between increased comorbidity
and poor quality of life has been conflicting.33,34 The pres-
ence of significant comorbidities among head and neck
cancer patients, and their significant impact on symptoms
including sleep quality, suggest the need to consider a
multidisciplinary approach to patients ensuring that all
aspects of care are addressed, rather than focusing atten-
tion solely on extirpation of their neoplasm.
Depressive Symptoms
Consistent with the literature, depression is quite com-
mon in head and neck cancer patients and associated with
poor sleep quality.35 Careful screening for depression in
head and neck cancer patients complaining of sleep distur-
bances is needed, especially given the fact that effective
counseling and medication therapies are available to treat
clinical depression. Given the anticholinergic side effects of
certain antidepressants and the high incidence of xerosto-
mia in this patient population, clinicians ought to query
patients with depression about xerostomia and carefully
consider which medications may be better tolerated among
depressed patients with head and neck cancer.
Smoking and Problem Drinking
Both smoking and drinking were significant predictors
of 1-year sleep quality in the bivariate analyses, but were
only marginally significant in the multivariate analyses.
Although the research on sleep quality among smokers is
limited, a large controlled trial demonstrated significantly
altered sleep architecture detected during polysomnogra-
phy in smokers, compared with nonsmokers and former
smokers.36 Nicotine is a stimulant that can keep people
awake. Moreover, nicotine cravings can arouse people from
sleep. Because tobacco use is a major causative agent for
head and neck cancer, and smoking predicts survival in this
population, cessation services must be readily available to
head and neck cancer patients; an added benefit may be
improved sleep quality.36
Patients with alcohol problems slept poorly com-
pared with their counterparts, although the association
was only marginally significant in the multivariate anal-
ysis. Alcohol’s direct negative effects on sleep are well-
known.10 In addition, alcohol is synergistic with nar-
cotics, on which many head and neck cancer patients
rely. From a practical standpoint, these results confirm
the need to monitor and screen for alcohol dependence
not only at the time of diagnosis, but also during surveil-
lance after treatment is complete.
Age and Sex
Younger patients with head and neck cancer had
significantly worse sleep than their older counterparts
in this study. This corroborates previous results, but is
contrary to the generally observed trend of worsening
sleep in older populations.21 Rogers et al. suggest that
this may be due to a matter of perception (younger
patients are more bothered by sleep disturbances,
whereas older patients expect it).23 There may be a
methodological limitation as well, as some data suggest
that subjective and objective measurements of sleep in
the elderly may be incongruous.37 Although studies have
shown that women have lower sleep scores than men,
sex was only marginally significant in the multivariate
analysis.22 This suggests that other factors, such as
symptoms and health behaviors, may override the effects
of sex on sleep among head and neck cancer patients.
CONCLUSION
The independent variables of pain and xerostomia
were major predictors of poor sleep quality among head
and neck cancer patients. The presence of a tracheotomy,
TABLE III.
Multiple Linear Regression Parameter Xerostomia on 1-Year Sleep
Score (N 5 457; R2 5 0.482).
Variable Parameter Estimate P Value
SF-36 bodily pain, 1 yr† 2.18 <.001
Xerostomia, 1 yr‡ 2.79 <.001
Radiation 0.30 .911
Chemotherapy 1.19 .560
Head and neck surgery (any) 1.06 .536
Current feeding tube 0.83 .690
Current tracheotomy 8.22 .037
Cancer site (vs. larynx)
Oral/sinus 0.04 .987
Pharynx* 0.62 .756
Stage IV cancer 0.74 .679
Moderate/severe comorbidity 3.97 .018
Depressive symptoms, 1 yr 14.27 <.001
Smoked past month, 1 yr 3.43 .087
Alcohol problem, 1 yr 4.54 .074
Age (decades) 2.39 <.001
Female gender 3.08 .080
†The SF-36 Bodily Pain Score and the MOS Sleep Score are meas-
ured on a scale of 0–100 with 100 being the best score.
‡Xerostomia is measured on a scale of 1–5 with 5 being the worst
score.
*Pharynx cancer site includes Oropharynx, Hypopharynx, Nasophar-
ynx, and Unknown Primary.
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comorbidities, depression, and younger age were statisti-
cally significant predictors of poor sleep 1 year after
diagnosis with head and neck cancer, whereas smoking
and problem drinking were marginally significant. Can-
cer site and cancer stage did not predict sleep quality.
Many factors adversely affecting sleep in head and neck
cancer patients are potentially modifiable (particularly
pain, xerostomia, depression, smoking, and problem
drinking). All clinicians involved in the treatment of
head and neck cancer patients can ably evaluate these
entities, which is especially important given that the tar-
geted treatment of these disorders is likely to improve
sleep quality and quality of life.
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